Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma

Bone Marrow Transplantation

Volumn 49, Issue 5, 2014, Pages 671-678

  Avivi, I ^a   Canals, C ^b   Vernant, J P ^c   Wulf, G ^d   Nagler, A ^e   Hermine, O ^f   Petersen, E ^g   Yakoub Agha, I ^h   Craddock, C ⁱ   Schattenberg, A ^j   Niederwieser, D ^k   Thomson, K ^l   Blaise, D ^m   Attal, M ⁿ   Pfreundschuh, M ^o   Passweg, J ^p   Russell, N ^q   Dreger, P ^r   Sureda, A ^s  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^l UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^m INSTITUT PAOLI CALMETTES   (France)

ⁿ CHU PURPAN   (France)

^o SAARLAND UNIVERSITY   (Germany)

^p UNIVERSITY HOSPITAL BASEL   (Switzerland)

^q NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

allo SCT; diffuse large B cell lymphoma; HLA identical sibling; matched unrelated donor

Indexed keywords

ALEMTUZUMAB; LYMPHOCYTE ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HLA MATCHING; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIBLING; T CELL DEPLETION; TREATMENT OUTCOME; UNRELATED DONORS; ADOLESCENT; AGED; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHILD; COMPARATIVE STUDY; DISEASE COURSE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84900301455     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.4     Document Type: Article

References (31)

1. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562-3568
2. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190
3. Van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348
4. Moore S, Peggs K, Thomson K, Lowry L, Ljubic A, Goldstone AH et al. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy. Br J Haematol 2012; 156: 142-143
5. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011: 498-505
6. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiplerelapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426-432
7. Maloney D. Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant 2008; 42(Suppl 1): S35-S36
8. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: Report of the Societe Francaise De Greffe De Moelle et De Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85
9. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, De Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316
10. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: A multicentre experience. Br J Haematol 2008; 143: 395-403
11. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 965-972
12. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1326-1334
13. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. Ann Hematol 2012; 91: 931-939
14. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: A report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35-45
15. Peniket AJ, Ruiz De Elvira MC, Taghipour G, Cordonnier C, Gluckman E, De Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678
16. Hamadani M, Benson Jr DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547-553
17. Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009; 147: 719-728
18. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131: 223-230
19. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935-1940
20. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633
21. EBMT MED-AB FORMS MANUAL. Available at http://www.ebmt.org/Contents/ Data-Management/Registrystructure/MED-ABdatacollectionforms/Documents/ MED-ABFormsManual.pdf Accessed in August 2012
22. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
23. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828
24. Gluckman E. Choice of the donor according to HLA typing and stem cell source. In: Apperley J, Carreras E, Gluckman E, Masszi T (eds). The ESH-EBMT Handbook: Hematopoietic Stem Cell Transplantation. 6th edn (Forum Service Editor, 2012, pp 86-102
25. Van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: Long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554-563
26. Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: A retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005; 36: 205-213
27. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871
28. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versuslymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653
29. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M et al. Reducedintensity conditioning followed by related allografts in hematologic malignancies: Long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011; 17: 1025-1032
30. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013; 19: 746-753
31. Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1196-1204.